A Study of Combination Therapy in Patients With Resectable Liver Cancer (NCT07684040) | Clinical Trial Compass
Not Yet RecruitingPhase 2
A Study of Combination Therapy in Patients With Resectable Liver Cancer
China68 participantsStarted 2026-08-01
Plain-language summary
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of an initial combination treatment strategy followed by surgery in patients with cancer. Eligible participants will receive combination therapy prior to surgical intervention. Patients who meet predefined surgical criteria will undergo hepatic resection. Following surgery, additional treatment may be administered according to the investigator's assessment. The primary objective is to evaluate time to treatment failure (TTF). Secondary objectives include evaluation of pathological response, resection outcomes, progression-related outcomes, survival outcomes, and safety.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
. Albumin ≥30 g/L; Total bilirubin ≤1.5 × ULN; ALT, AST, and ALP ≤5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance \>50 mL/min.
. INR ≤2.3 or PT prolongation ≤6 seconds.
. Urine protein \<2+; if ≥2+, 24-hour urine protein \<1.0 g.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This is a Phase 2 trial for resectable liver cancer — does that mean there's still limited data on how safe or effective this combination therapy is, and what do you know about the treatments being combined so far?
2Since the trial is measuring 'time to treatment failure' as its main goal, what does that actually mean for my situation — is it looking at how long the treatment keeps working before the cancer progresses or I have to stop due to side effects?
3The trial isn't recruiting yet — how long do you think it might be before it opens, and should I be pursuing surgery or another treatment option in the meantime rather than waiting?
4My cancer has been described as resectable, meaning surgery is an option — is there a reason to consider this combination therapy trial instead of, or before, having surgery, and what are the trade-offs?
5If I were to eventually enrol in this trial, what would the treatment schedule and follow-up visits look like, and is that something that would be realistic given my current health and daily life?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Time to Treatment Failure
Timeframe: 24 months
Trial details
NCT IDNCT07684040
SponsorAffiliated Hospital of Guangdong Medical University